Survival benefit of maintenance therapy in AML: a retrospective study in Iran
Author:
Affiliation:
1. Mashhad University of Medical Sciences
2. Mazandaran University of Medical Sciences
3. Psychosocial Health Research Institute, Iran University of Medical Sciences
4. Tehran University of Medical Sciences
Abstract
Publisher
Research Square Platform LLC
Reference27 articles.
1. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients;Burnett AK;Blood,2015
2. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation;Stone RM;N Engl J Med,2017
3. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia;Borthakur G;Am J Hematol,2014
4. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤ 60 years with newly diagnosed acute myeloid leukemia;Nazha A;Am J Hematol,2013
5. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial;Burnett AK;J Clin Oncol,2013
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3